<DOC>
	<DOCNO>NCT02636192</DOCNO>
	<brief_summary>The purpose study compare incidence diabetic ketoacidosis ( DKA ) among participant diagnose type 2 diabetes mellitus ( T2DM ) pair-matched exposure propensity score new use sodium-glucose co-transporter 2 inhibitor ( SGLT2i ) versus new use various antihyperglycemic agent ( AHAs ) , combine one group .</brief_summary>
	<brief_title>Study Incidence Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 ( SGLT2 ) Inhibitors Other Antihyperglycemic Agents</brief_title>
	<detailed_description>This study overall retrospective , observational , new-user cohort study use 4 large administrative claim databases US . Participants diagnose T2DM initiate SGLT2i AHAs ( metformin , sulfonylurea ( SU ) , thiazolidinediones ( TZDs ) , DPP-4 inhibitor ( DPP4i ) , GLP-1 agonist , insulin , AHAs ) April 1 , 2013 end claim data availability include study estimate incidence rate DKA different AHA new-user group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>At least 1 antihyperglycemic agent ( AHA ) prescription ( Rx ) study period , 4/1/2013 9/30/2014 . Diagnosed type 2 diabetes mellitus Enrollment history least 12 month Having prescription drug coverage Having prescription index drug 6 month prior Participants receive diagnosis type1 diabetes mellitus ( T1DM ) and/or secondary diabetes mellitus ( SDM ) time index date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sodium-glucose co-transporter 2 inhibitor</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
</DOC>